Proteome Sciences PLC (PRM.L): Preliminary Results for the Year Ended 31st December, 2010  
5/27/2011 12:04:56 PM

Commenting on these results, Christopher Pearce, Chief Executive of Proteome Sciences, said:

“With the already considerable and growing portfolio of highly developed biomarkers, biomarker assays and the state of the art protein biomarker CRO capability Proteome Sciences now has under its belt, combined with a major increase in marketing and business development, the Board is most confident of achieving significant growth in revenues in the year ahead and beyond.

2010 was a year of transition for Proteome Sciences. We significantly strengthened the balance sheet, installed state of the art mass spectrometry equipment to service our fast-growing pipeline of biomarkers and biomarker services and secured new contracts with bluechip companies. We also concluded the long standing warranty claim with Sanofi-Aventis which will free up a significant amount of executive time to deliver sales and revenue growth from all three parts of the business.

The recognition across the healthcare industry and by the major global regulators of the need for and utility of blood biomarkers for diagnostic, patient monitoring, drug selection and drug development purposes, further underpins our confidence in the business.”